1430089-58-9
Chemical Structure
N-Deshydroxyethyl Dasatinib-C3-NH2
Synonym(s): N-Deshydroxyethyl BMS-354825-C3-NH2
- CAS No.: 1430089-58-9
- Formula:C23H29ClN8OS
- Molecular Weight:501.05
SMILES: O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCCN)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl
Biological Activity: N-Deshydroxyethyl Dasatinib-C3-NH2 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for LCK (HY-107447) and a PROTAC linker (HY-76667), which recruits E3 ligases. N-Deshydroxyethyl Dasatinib-C3-NH2 can be used for synthesis of PROTAC SJ11646 (HY-175281)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Deshydroxyethyl Dasatinib-C3-NH2 | N-Deshydroxyethyl Dasatinib-C3-NH2 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for LCK (HY-107447) and a PROTAC linker (HY-76667), which recruits E3 ligases. N-Deshydroxyethyl Dasatinib-C3-NH2 can be used for synthesis of PROTAC SJ11646 (HY-175281). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yang JJ, et al. LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia. bioRxiv [Preprint]. 2025 Jul 7:2025.07.03.663042. [Content Brief]
- [2]. Hu J, et al. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia. Sci Transl Med. 2022 Aug 24;14(659):eabo5228. [Content Brief]
Keywords